Skip to main content
. Author manuscript; available in PMC: 2008 Dec 8.
Published in final edited form as: Cancer Res. 2007 Sep 1;67(17):7960–7965. doi: 10.1158/0008-5472.CAN-07-2154

Fig 3.

Fig 3

Inhibitors of EGFR cooperate with the dual PI3Kα/mTOR inhibitor PI-103 to arrest growth of PTEN-mutant human glioma cells. LN229:EGFR (PTENwt) and U87:EGFR (PTENmt) cells were treated with erlotinib, PI-103, or erlotinib plus PI-103 at indicated dosages. (A) Proliferation was visualized by crystal-violet staining of cells after treatment for 72 hr (top panel). Flow cytometry analysis (bar graph-bottom panel) shows effects on cell cycle after treatment for 24 hr. Percentage of cells in G0G1, S, and G2M phases of the cell cycle is indicated. (B) Cells were treated same as in (A). EGF was added 15 min prior to harvest. Lysates were subjected to immunoblot analysis with antisera indicated.